These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38049240)

  • 21. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes.
    Kato GJ; Gladwin MT; Steinberg MH
    Blood Rev; 2007 Jan; 21(1):37-47. PubMed ID: 17084951
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth differentiation factor-15 in young sickle cell disease patients: relation to hemolysis, iron overload and vascular complications.
    Tantawy AA; Adly AA; Ismail EA; Darwish YW; Ali Zedan M
    Blood Cells Mol Dis; 2014 Dec; 53(4):189-93. PubMed ID: 25065856
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endothelial Nitric Oxide Synthase (eNOS) Gene Polymorphisms and Markers of Hemolysis, Inflammation and Endothelial Dysfunction in Brazilian Sickle Cell Anemia Patients.
    Chenou F; Albuquerque DM; Leonardo DP; Domingos IF; Bezerra MAC; Araújo AS; Blotta MHSL; Costa FF; Sonati MF; Paula EV; Santos MNN
    Biochem Genet; 2020 Aug; 58(4):580-594. PubMed ID: 32277314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Defective regulation of complement by the sickle erythrocyte: evidence for a defect in control of membrane attack complex formation.
    Test ST; Woolworth VS
    Blood; 1994 Feb; 83(3):842-52. PubMed ID: 7507737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemolysis and hemolysis-related complications in females vs. males with sickle cell disease.
    Raslan R; Shah BN; Zhang X; Kanias T; Han J; Machado RF; Gladwin MT; Gordeuk VR; Saraf SL
    Am J Hematol; 2018 Nov; 93(11):E376-E380. PubMed ID: 30117177
    [No Abstract]   [Full Text] [Related]  

  • 26. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature.
    Haymann JP; Stankovic K; Levy P; Avellino V; Tharaux PL; Letavernier E; Grateau G; Baud L; Girot R; Lionnet F
    Clin J Am Soc Nephrol; 2010 May; 5(5):756-61. PubMed ID: 20185605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hemolysis-associated priapism in sickle cell disease.
    Nolan VG; Wyszynski DF; Farrer LA; Steinberg MH
    Blood; 2005 Nov; 106(9):3264-7. PubMed ID: 15985542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fatal hemolysis induced by ceftriaxone in a child with sickle cell anemia.
    Bernini JC; Mustafa MM; Sutor LJ; Buchanan GR
    J Pediatr; 1995 May; 126(5 Pt 1):813-5. PubMed ID: 7752012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiopulmonary complications of sickle cell disease: role of nitric oxide and hemolytic anemia.
    Gladwin MT; Kato GJ
    Hematology Am Soc Hematol Educ Program; 2005; ():51-7. PubMed ID: 16304359
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated pulse pressure is associated with hemolysis, proteinuria and chronic kidney disease in sickle cell disease.
    Novelli EM; Hildesheim M; Rosano C; Vanderpool R; Simon M; Kato GJ; Gladwin MT
    PLoS One; 2014; 9(12):e114309. PubMed ID: 25478953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inflammation, Hemolysis, and Erythropoiesis Lead to Competitive Regulation of Hepcidin and Possibly Systemic Iron Status in Sickle Cell Disease.
    Ginzburg YZ; Glassberg J
    EBioMedicine; 2018 Aug; 34():8-9. PubMed ID: 30076048
    [No Abstract]   [Full Text] [Related]  

  • 32. Albuterol-induced myocardial ischemia in sickle cell anemia after hemolysis from ceftriaxone administration.
    Corso M; Ravindranath TM
    Pediatr Emerg Care; 2005 Feb; 21(2):99-101. PubMed ID: 15699818
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Haptoglobin Genotypes Associated with Vaso-Occlusive Crisis in Sickle Cell Anemia Patients of Eastern India.
    Meher S; Mohanty PK; Patel S; Das K; Sahoo S; Dehury S; Mohapatra MK; Jit BP; Das P; Dash BP
    Hemoglobin; 2021 Nov; 45(6):358-364. PubMed ID: 33393394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab as an effective treatment of hyperhemolysis syndrome in sickle cell anemia.
    Bachmeyer C; Maury J; Parrot A; Bachir D; Stankovic K; Girot R; Lionnet F
    Am J Hematol; 2010 Jan; 85(1):91-2. PubMed ID: 20029943
    [No Abstract]   [Full Text] [Related]  

  • 35. Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.
    Ataga KI; Stocker J
    Expert Opin Investig Drugs; 2009 Feb; 18(2):231-9. PubMed ID: 19236269
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Resistance of sickle cells to saponin-induced hemolysis.
    Tatsumi N; Matsumoto H; Bruce S; Schwarz E; Asakura T
    Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):886-92. PubMed ID: 4060982
    [No Abstract]   [Full Text] [Related]  

  • 37. Does consumption of mega-doses of ascorbic acid pose a hemolytic risk to persons with sickle cell trait and sickle cell anemia?
    Calabrese EJ
    Med Hypotheses; 1982 Dec; 9(6):647-9. PubMed ID: 7167075
    [No Abstract]   [Full Text] [Related]  

  • 38. Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!
    Gladwin MT; Kato GJ
    Haematologica; 2008 Jan; 93(1):1-3. PubMed ID: 18166776
    [No Abstract]   [Full Text] [Related]  

  • 39. The role of Complement in Post-Transfusion Hemolysis and Hyperhemolysis Reaction.
    Roumenina LT; Bartolucci P; Pirenne F
    Transfus Med Rev; 2019 Oct; 33(4):225-230. PubMed ID: 31672341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lactate dehydrogenase in sickle cell disease.
    Stankovic Stojanovic K; Lionnet F
    Clin Chim Acta; 2016 Jul; 458():99-102. PubMed ID: 27138446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.